Canagliflozin Surpasses Sitagliptin as Diabetes Add-On
October 10, 2012|Clinical Endocrinology News
Author and Disclosure Information
AT THE ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
The study was sponsored by Janssen, the company developing canagliflozin. Dr. Schernthaner said that he has received honoraria and research funding from Janssen, AstraZeneca and Bristol-Myers Squibb, the companies developing dapagliflozin, and from Boehringer Ingelheim, the company developing empagliflozin. Dr. Zinman said that he has received honoraria and research funding from Johnson & Johnson (the parent company of Janssen), and Boehringer Ingelheim and other drug companies. Dr. Gallwitz said that he has received honoraria and research funding from Boehringer Ingelheim, AstraZeneca and Bristol-Myers Squibb, and other drug companies.
